التفاصيل البيبلوغرافية
| العنوان: |
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia |
| المؤلفون: |
Branagan, Andrew R., Lei, Matthew M, Maron, Jenny S, Yee, Andrew J, O'Donnell, Elizabeth, Castillo, Jorge J., Raje, Noopur S., Treon, Steven P, Flynn, Catherine A, Mo, Clifton C., Nadeem, Omar, Richardson, Paul G., Panaroni, Cristina, Meid, Kirsten, Bernstein, Zachary S., Lyons, Rebecca T., Hunter, Zachary R, Guerrera, Maria Luisa, Gammon, Marilyn T., Lively, Kathleen J., Packer, Lisette, Waterman, Matthew, Gallagher, Raquel, Juleg, Boris, Alter, Galit, Sarosiek, Shayna |
| المصدر: |
Blood |
| بيانات النشر: |
American Society of Hematology. Published by Elsevier Inc. |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological, envir, socio |
| الوصف: |
BACKGROUND: Multiple myeloma (MM) and Waldenström macroglobulinemia (WM) are associated with significant immunoparesis. Based on the ongoing COVID-19 pandemic, there is an urgent need to understand whether patients are able to mount a sufficient response to COVID-19 vaccines. METHODS: MM and WM patients are vaccinated with mRNA-1273 (Moderna), BNT162b2 mRNA (Pfizer/BioNTech), or JNJ-78436735 (Johnson & Johnson) in a prospective clinical trial. Primary endpoint is SARS-CoV-2 spike protein (S) antibody (Ab) detection 28 days after final vaccination. Secondary endpoints include functional serologic assessments and T-cell responses at 28 days, 6 months, 9 months, and 12 months following vaccination. S Abs were detected by Elecsys assay (Roche Diagnostics), with ³ 0.80 U/mL defined as positive and titers > 250 U/mL considered stronger correlates of neutralization. SARS-CoV-2 wildtype and variant S-specific Ab isotypes and FcγR binding profiles were quantified by custom Luminex assay. Antibody-dependent neutrophil and cellular phagocytosis (ADNP and ADCP) were assessed using flow cytometry. RESULTS: To date 141 patients have been enrolled, 137 (91 MM and 46 WM) of whom had an S Ab assessment. Median Ab titer was 178.0 (IQR, 16.10-1166.0) for MM and 3.92 (IQR, 0-278.9) for WM. S Ab response rate was 91% (83/91) in MM and 56% (27/46) in WM. However, responses achieving S Ab >250 U/mL were 47.3% (43/91) in MM and 26.1% (12/46) in WM. In patients ³75 years, responses >250 u/mL were 13.3% (2/15; p250 u/mL following mRNA-1273, BNT162b2, and JNJ-78436735 were 67.6% (23/34; p250 u/mL occurred in 30% (6/20) as opposed to 55.6% (30/54) for VGPR+ (p<0.05). MM patients having autologous stem cell transplant within 12 months demonstrated 100% (5/5; p<0.05) S Ab . |
| نوع الوثيقة: |
text |
| اللغة: |
English |
| العلاقة: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701550Test/ |
| الإتاحة: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701550Test/ |
| حقوق: |
undefined |
| رقم الانضمام: |
edsbas.52A7EF52 |
| قاعدة البيانات: |
BASE |
